Amgen said it is eliminating about 380 positions in research and development to focus resources on its late-stage drug pipeline. "It's very expensive to conduct clinical trials," said spokeswoman Mary Klem. "The patient population gets bigger at each phase. That's the crux of what is causing us to make these strategic changes."

Related Summaries